Safe Harbor Statement

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2023 financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, constant currency revenue growth, foreign currency translation revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; management’s expectations for the impact of foreign currency and acquisitions, and for future financial and operational performance and business outlook; future economic conditions; the duration and impact of supply chain and geopolitical challenges; strategic investments; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to COVID-19, the length and severity of any recession and the impact on global economic conditions, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from its ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, continued volatility in the capital markets, the impact of increased interest rates, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, the impact of foreign currency exchange rates, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2022, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
BRUKER CORPORATION 2023 INVESTOR DAY

Agenda
11:00 am to 1:30 pm EDT

01
Bruker Strategy - Proteomics & Spatial
Frank H. Laukien, President & CEO

02
Unbiased, Deep 4D-Proteomics on timsTOF
Rohan A. Thakur, President, Life Sciences MS (Video)

03
Proteomics Drug Discovery Services & Tools
Oliver Rinner, President, Biognosys (Video)

04
Break

05
Spatial Biology and Cell Microscopy
Mark Munch, President, Bruker NANO

06
In-vivo Microscopy in Neuroscience Research
Kunal Ghosh, CEO, Inscopix and Xiaomei Li, Bruker VP & GM, Fluorescence Microscopy (Video)

07
Medium-Term Outlook 2026
Gerald Herman, Chief Financial Officer

08
Q&A Session
Adjourn
Key takeaways of Investor Day 2023: *Disciplined entrepreneurialism at work*

- **Project Accelerate 2.0 has transformed Bruker** into a higher organic growth company
- Goal to grow revenue organically 200-300 bps above market in 2023-2026
- Dual Strategy of *Project Accelerate* & *Operational Excellence* delivers solid margin expansion
- Goal to grow non-GAAP EPS in double digits in 2023-2026, with continued high RoIC
- *Bruker Management Process* and culture of *Disciplined Entrepreneurialism* drive profitable growth
- Bruker investing to seize large secular opportunities in *Proteomics* and *Spatial Biology*
- **timsTOF 4D-Proteomics** is game-changing and drives unbiased proteomics
INVESTOR DAY 2023

Bruker at a Glance

- Leading provider of high-value life science tools and solutions
- #1 or #2 market position in majority of our portfolio
- Deep expertise in physics, chemistry, and biology
- Organic growth, innovation and high RoIC philosophy

$2.8B<sup>(1)</sup> Revenue
8,500 Colleagues
R&D ~10% of Revenue

2022 BSI<sup>(2)</sup> Markets

- Applied/Food: 10%
- Semi-Metrology: 10%
- Microbiology: 4%
- BioPharma: 16%
- Industrial & GreenTech: 21%
- Academic & Government: 39%

Repositioned for Strong Secular Trends, Diversified Markets Mitigate Risk

2022 Project Accelerate 2.0

- Project Accelerate 2.0 Drives Revenue Growth & Margins
- PA 2.0: 56%
- Bruker Core: 44%

2022 BSI<sup>(2)</sup> by Geography

- US: 30%
- Europe: 34%
- Asia: 36%

Balanced Mix, with Recent Rapid Growth in US

(1) 2023 guidance. (2) Bruker Scientific Instruments (BSI) revenue reflects sum of BSI BioSpin, BSI CALID and BSI Nano Segments
**Mission: Customer Success**
Our high-performance scientific instruments, life science research and diagnostic solutions, and comprehensive support, enable our customers’ discoveries and innovation, and drive their productivity and success.

**Driven by Purpose & Passion**
We are driven to make important contributions to the health, prosperity and safety of humankind. Via scientific, technological, diagnostic and business innovations, we create sustainable value for our customers, partners, colleagues and shareholders.

**Values: Integrity & Quality**
We value integrity, respect and trust within a fast-paced and dynamic environment built around scientific solutions. Ethical behavior, equal opportunity, inclusivity, compliance and commitment are at the heart of our business.

**Our Unique Culture**
We foster a diverse, high-performance culture of **disciplined entrepreneurialism**. We are caring, inclusive and people-oriented. We drive innovation, aim for breakthroughs, operate with discipline and good processes, all with passion and commitment.
Dual strategy of *Project Accelerate 2.0* and Operational Excellence works

**Project Accelerate 2.0 Initiatives**

- **Pull up** growth and margins
- Re-positioning Bruker for high-growth, high-margin opportunities
- Innovating to push envelope in sensitivity, resolution, quantification, throughput.
- Building unique, leading platforms for novel applications, life-science solutions
- Solving complex biology in large TAMs with strong secular growth
- *Project Accelerate 2.0 at ~56% of revenue, with DD revenue CAGR*

**Operational Excellence**

- **Pushes up** market share, margins
- Cadence and control of Bruker Management Process drives execution and predictability
- Includes commercial and product R&D excellence
- Disciplined financial execution: significant investments and margin expansion, high ROIC
- Prudent capital allocation with conservative margin of safety

---

© 2023 Bruker
Bruker transformation accelerates value-creation for all stakeholders

2014-2016: RESTRUCTURING & TRANSFORMATION PHASE
- Cost out, consolidation and divestitures
- New organization & management process
- Integrated ERP, SF CRM adoption
- New HR compensation/incentives
- Increased outsourcing

2017-2020: PROJECT ACCELERATE & OPERATIONAL EXCELLENCE
- Portfolio transformation
- Entrepreneurial Bruker Management Process
- Improved productivity
- Shared services centers
- Enhanced compliance & risk management

2021-202X: PROJECT ACCELERATE 2.0 & OPERATIONAL EXCELLENCE
- Major focus Proteomics and Spatial Biology
- Microbiology & Molecular DX
- Biopharma & Applied, Semi Metrology
- Aftermarket, Consumables & Software
- Further improved productivity, tax rate, FCF

Organic Revenue CAGR
- 2% (2012-18)
- 8% (2018-23G)

Non-GAAP EPS CAGR
- 2% (2012-18)
- 9% (2018-23G)

ROIC
- >20% (2018-2022)

G = guidance midpoint

© 2023 Bruker
Faster Growth from Project Accelerate 2.0 High-Growth, High-Margin Initiatives

- **Unbiased Proteomics & Multiomics**
  - Proteomics, PTMs, multiomic LBx, tissue SpatialOMx, *functional* structural biology, biomolecular condensates, unbiased single-cell proteomics

- **Assays, Software & Aftermarket**
  - Consumables, assays, services, libraries & scientific software

- **Next-gen Nanomaterials Research & Semi Metrology**
  - Enabling R&D and QC of next-gen logic, memory, displays, renewable energy, nanotools and nanomaterials, Greentech

- **Spatial Biology, Single-Cell Omics, and Cellular Analysis**
  - Super-resolution microscopy & cytometry for immunology, oncology, single-cell and subcellular spatial biology and targeted multiomics; Acuity Spatial 3D Genomics

- **Biopharma & Applied**
  - High-value NMR, MS and FTIR/NIR solutions for drug discovery, development and pharma PAT; Applied food analysis and forensics

- **Microbiology & Molecular Dx**
  - High-value solutions for faster, accurate and broadly scalable infectious disease diagnostics, including viral MDx

© 2023 Bruker
MALDI Biotyper® with Novel Applications
Installed Base Grows Steadily

- Leader in microbial identification by proteomic fingerprinting in clinical and applied markets
- Better, faster, more cost-effective ID of bacteria and fungi
- Near-universal microbial ID species coverage from cultures

Technology Leadership
- MALDI-TOF technology leadership
- MALDI Biotyper® sirius enables novel lipidomics assays - research use only
- Sepsityper FDA clearance in Dec. 2020 accelerates US growth
- MBT Compass HT IVD software increases speed up to 600 samples/hr

Market Expansion & Installed Base Growth
- >5,500 MALDI Biotyper® installed base
- >100 million IDs per year on MALDI Biotyper®
- Majority of revenues is recurring. Strong assay, consumables and service aftermarket growth
Establishing NMR and EPR as Core Analytical Techniques in Battery Value Chain: Research, Production & Recycling

INVESTOR DAY 2023 - CLEANTECH

Mining → Materials → Cell → Packing → Integration → Recycling

Electrode Production:
- Mixing
- Coating
- Drying
- Solvent Recovery
- Calendering
- Slitting

Battery Cell Conditioning:
- Formation
- Aging

Battery Recycling:
- End-of-Life
- Shredding
- Electrolyte Recovery
- Upcycling Re-Lithiation

Innovation with Integrity
June 15, 2023
Clean Energy Developments with BEST Cleantech Technologies

- **Growing Cleantech markets** for differentiated and unique BEST cleantech tools (‘picks & shovels’)
- BEST offers **cleantech technologies** for fusion power and next-gen offshore wind turbines

Fusion Research & Pilot Fusion Power Plants

- **Magnetic confinement fusion** holds promise as clean, abundant, renewable, efficient and safe energy source to replace fossil fuel plants and nuclear fission reactors in the future
- Bruker and RI received ~$65M of multi-year orders for key technologies for **major fusion projects in Europe and Asia**
- Bruker is co-founder of **Gauss Fusion Initiative** (www.gauss-fusion.com)

- **Inner Vertical Targets** (above) by majority-owned RI Research Instruments to withstand extreme plasma heat loads at ITER
- RI recently received new subcontract for **plasma heating technologies for ITER**
- Novel, high-current metallic **RRP® superconductors** (left) by BEST for a magnetic confinement fusion pilot in Asia (recently received 2nd tranche order)

Superconductors for Wind Turbines

- Superconductors enable novel **efficient, smaller, and lighter-weight high-power wind turbines** for offshore wind applications
- Superconductors could replace **rare earth materials** in future high-power wind turbine designs
- Bruker has delivered high performance superconductors for an off-shore wind turbine prototype in the US
From new Chip Structures to new Back-end 3D Packaging – Enabled by next-gen advanced semiconductor metrology by Bruker

**X-Ray Diffraction Enables Next-Generation Chip Manufacturing**

- **Sirius-XRD**
  10x faster throughput. Shipped first beta system in early 2022

- **Won first multi-tool orders for pilot production monitoring at 3 leading semiconductor manufacturers**

- **Sirius-XRD**

  Ge concentration in the GAA stack defines etch rate later in the process

- **ContourSP-S**
  35% throughput improvement

- **InSight-WLI**
  New, high resolution, wafer level packaging metrology

**Advanced QC for 3D Chips Packaging**

- **ContourSP-S**
  - Chip packaging has moved to 3D
  - We enable micron scale interconnect process control

- **InSight-WLI**
  - New, high resolution, wafer level packaging metrology
Functional Structural Biology: Understanding Disease Biology with GHz NMR

**NMR in (Un-)structural Biology**
Intrinsically Disordered Proteins (IDPs)
- IDPs implicated in protein aggregation in Alzheimer’s, Parkinson’s, Diabetes-II and Creutzfeldt-Jakob diseases

**NMR in RNA–Protein Complexes**
Accelerates RNA Drug Discovery
- RNA structure & RNA-target interactions
- RNA pathways and RNA-binding

**NMR in Pharmacology**
GPCRs as Key Drug Targets
- NMR key to G-Protein Coupled Receptors (GPCR) conformational states

**NMR in 4D-Biology**
Biological Processes in Space and Time
**AI Technology in NMR Structural Biology**

Automated protein structure assignment

**Ultra High-speed 160 kHz Magic-Angle Spinning Probes**

Revolutionary speed to study membrane proteins, amyloid fibrils

**Revolutionary, unique 1.0/1.1/1.2 GHz Systems**

2022: Launch of compact 4K 1.0 GHz Ascend Evo

\[ ^{15}\text{N},^{13}\text{C}-\text{labelled} \sim 100 \text{ kDa membrane protein} \]

ETH Zürich Collaboration

GHz-class installed or in backlog: 26 units

Two UK 1.2GHz orders
Seizing Very Large TAMs and Secular Growth Opportunities in Proteomics & Spatial Biology

Essential
Proteins and metabolites perform most functions in the body

Complex
~21k genes, yet millions of proteoforms, infinite PTM combinations in biology

Virtuous Cycle
Ever more sensitive instruments and powerful software unlocking deeper biological insights, for more precise diagnosis and better therapeutics

Still early innings of understanding

Image shows a human colon cancer FFPE sample imaged with Canopy’s CellScape Spatial Immune Profiling Kit
INVESTOR DAY 2023 - PROTEOMICS & SPATIAL BIOLOGY

Proteomics, Structural Biology, Metabolomics/Lipidomics, Applied & Clinical Proteomics (MBT), Spatial Biology & Cellular Microscopy

2022 Bruker Revenue Mix


- MALDI Biotyper
  Applied & Clinical Proteomics
- timsTOF
  4D-Proteomics
  4D-Multiomics
- Crystallography
- NMR functional structural biology
- CellScape Spatial Biology, Cellular FM
Innovations in Tissue Proteomics Sample Prep and Immunopeptidomics

Novel BeatBox FFPE Workflow

“This breakthrough allows us to process large cohorts of FFPE tissue quickly, reproducibly, and with greater precision, enabling large-scale biobank projects. By leveraging BeatBox technology, we uncover deep proteomics insights in tissue pathology research.”

Dr. Michael Wierer, Director Proteomics Research Infrastructure, University of Copenhagen

Novel AI-Bioinformatics for timsTOF SCP-based Immunopeptidomics

• Unmatched sensitivity of timsTOF SCP coupled to PaSER Novor algorithm delivers significant performance boost for immunopeptidomics, for small tumor biopsy samples

• PaSER Novor derives peptide sequences de novo after training with >1.7M timsTOF data sets for real-time GPU-enabled proteomics
Inscopix and Biognosys add Key Capabilities in Neuroscience Research and Proteomics

**Inscopix** is a neuroscience pioneer and market leader of miniaturized microscopes for freely moving animal brain imaging, empowering breakthroughs in fundamental neuroscience brain circuitry research.

- Enhances Bruker's position as a technology leader for in-vivo brain functional imaging with Ultima multiphoton microscopes and preclinical MRI systems.

FY2022 revenues ~$20M

>60% Gross Margins

+Double Digit % Expected Revenue CAGR

Expected to become Accretive to Operating Margin over time

**Biognosys** offers mass spec expert proteomics CRO services, software and kits for deep, peptide-level proteome insights in drug discovery and development.

- Expect unique synergies between Biognosys proprietary proteomics services, software and kits, and Bruker’s timsTOF 4D Proteomics applications.

FY2022 revenues ~$15M

+Double Digit % Expected Revenue CAGR

Expected to become Accretive to Operating Margin over time
timsTOF Platform Advancing 4D-Proteomics

- Unmatched Robustness (~60 SPD – 200 SPD)
- Unparalleled Duty Cycle (PASEF, diaPASEF, prmPASEF, capsPASEF)
- High-Throughput Omics (5min, 20min methods)
- Identify more PTMs (Mobility Offset Mass Aligned – MOMA)
- Higher Confidence ID with CCS values (TIMScore, CCS-Predict, ML)
- Single Cell Proteomics (Deep Visual, MALDI-Guided, LCM spatial proteomics)

timsTOF Platform:
Unbiased discovery at depth and scale with 1% FDR, and without antigen cross-reactivity

Update June 2023:
- Installed Base >700 units
- timsTOF Ultra at ASMS ’23

timsTOF HT: More than 100,000 unique peptides identified with 60-minute nLC gradient using dia-PASEF method
Key takeaways of Investor Day 2023: *Disciplined entrepreneurialism at work*

- **Project Accelerate 2.0 has transformed Bruker** into a higher organic growth company
- Goal to grow revenue organically 200-300 bps above market in 2023-2026
- Dual Strategy of *Project Accelerate* & *Operational Excellence* delivers solid margin expansion
- Goal to grow non-GAAP EPS in double digits in 2023-2026, with continued high RoIC
- *Bruker Management Process* and culture of *Disciplined Entrepreneurialism* drive profitable growth
- Bruker investing to seize very large secular opportunities in *Proteomics* and *Spatial Biology*
- *timsTOF 4D-Proteomics* is game-changing and drives unbiased proteomics
Bruker Investor Day
4D-ProteOMICS with the Game-Changing timsTOF Platform

Rohan A. Thakur, Ph.D.
President
Life Sciences Mass Spectrometry
The timsTOF Pro (HUPO’ 17) enabled Proteomics to hit ‘Refresh’

- Unmatched Robustness
  (~60 SPD – 1000 SPD)

- Unparalleled Duty Cycle of TIMS+TOF MS
  (PASEF, diaPASEF, prmPASEF, capsPASEF…)

- Identify more PTMs with power of TIMS
  (Mobility Offset, Mass Aligned - MOMA)

- Higher Confidence ID with CCS-enablement
  (TIMScore, CCS-Predict, Machine Learning)

- GPU- based Informatics for CCS-enabled search
  (Run & Done introduced)

- Sensitivity for low sample amounts & single cells
  (empowering immunopeptidomics, de novo)

‘Proteomics at Scale’

✓ Speed ✓ Robustness ✓ Sensitivity ✓ Specificity
A Differentiated Ecosystem to Accelerate Discovery

Key Drivers:

- Immunopeptidomics
- Single-cell proteomics (esp. tumor biology) & fundamental research
- Target (protein) selection
- Chemical Proteomics
- Drug re-purposing
- Therapy personalization

Framing knowledge by the study of “Protein-to-Phenotype” proteogenomic connections (plasma) that allow for:

- Shared disease etiologies
- Patient stratification

And our partners CTC, EvoSep, IonOptiks, Cellenion, SEER, Tecan, Agilent, Mass Dynamics, maxQuant, Skyline & Rapid Novor
Today, the most popular bioinformatics packages use CCS values; maxQuant, MS Fragger, PEAKS, Spectronaut, Skyline, & AlphaPept are all CCS-enabled.

https://doi.org/10.1016/j.cels.2021.06.006
Users Embracing the Benefits of PASEF

- Near 100% utilization of ions due to parallelization boosted sensitivity
- Proteomics at scale (>50SPD) now routine.
- Short gradients (~3 min) with acceptable depth now possible.
- Discover more PTMs due to the specificity of MOMA (mobility offset, mass aligned).
- Confidence benefit of TIMScore for low S/N peptide identification.
Peer Group Recognition for the Advances Made

EuPA’20 Technology award for PASEF

The Science and Technology Award recognizes an individual or team in private industry who played a key role in commercialization of a proteomics technology product, or procedure. The emphasis for the award is on making the technology, product, or procedure widely available, which is different from the basic scientific innovation.

Sponsored by the EUPAC Industrial Advisory Board

Melvin A. Park and Oliver Radtke, Bruker Daltonics Inc.

Mei Park and Oliver Radtke are recognized for the commercialization of the Trapped Ion Mobility Spectrometry (TIMS), Parallel Accumulation Serial Fragment (PASEF) method, which takes advantage of the unique features of the TIMS device to improve MS/MS sequencing speed and sensitivity on LC/MS Instruments. TIMS was developed as a compact and convenient way to perform true ion mobility measurements using an electric field gradient to trap ions in a flowing gas. A 5 cm TIMS device achieves the same resolution as 2 meter-long drift tube ion mobility system, with the high voltages and ion losses. Coupling the TIMS/PASEF method is transformable with the combination of increased MS/MS speed with improved sensitivity is helping to revolutionize the field of proteomics. Improving protein coverage and sample throughput such as studies of large clinical cohorts, e.g., plasma proteomics or urine proteomics. High sensitivity proteomics for single cell, immunoepitomics, and proteomics of tissue biopsies. Label free quantitation, SILAC, DIG and PRM proteomics are all applicable to the TIMS/PASEF instrument.

EuPA’22 Technology award for timsTOF SCP

Transfer Award from the University of Münster for timsTOF fleX MALDI-2
The Passion to **Innovate with Integrity** is hard-wired in our DNA
Making the Invisible, **Visible**, One Cell at a Time

### Capabilities of the new **timsTOF Ultra**

- Raises the bar for analytical **sensitivity** due to 5 key innovations:
  - New CSI-Ultra source with enhanced vortex gas delivery
  - Optimized conductive glass capillary for brighter beam
  - TIMS XR cell (4th generation)
  - HDR 14bit digitizer
  - All timsTOF SCP units are upgradeable (starting mid-Q1’24)

### Common vs Unique to Ultra

- >5.5K Protein Groups & >55K peptides at 125pg (1% FDR)

---

https://pax-db.org/


© 2023 Bruker For Research Use Only. Not for use in clinical diagnostic procedures.
Spatial Proteomics: Mouse Liver FFPE at the Max Delbruck Center for Molecular Medicine, Berlin.

“The single-cell sensitivity diaPASEF workflow on the timsTOF Ultra has brought our low-input tissue proteomics work to a new level. Using a 20min gradient with diaPASEF, we can reproducibly quantify 1,500–2,000 proteins from laser microdissected mouse liver FFPE tissue of only 1.5um regions, or approximately 1-2 hepatocytes”.

Dr. Fabian Coscia
Group Leader
Spatial Proteomics
MDC Berlin, Germany
“It would make biological sense to detect 6000 or more proteins in a single-cell equivalent experiment. The timsTOF Ultra has successfully overcome these barriers, allowing us to explore the proteome of individual cells at lightning-fast speeds and unparalleled sensitivity, even from minute samples.”

*Prof. Dr. Karl Mechtler is the 2023 winner of the prestigious Juan Albar Proteome Pioneer Award from the European Proteomics Assoc. to recognize his contributions in proteomics over several decades.*
The Unique Value of TIMS for Immunopeptidomics: The Carr Group, The Broad Institute, Cambridge, USA.

https://doi.org/10.1016/j.mcpro.2023.100563
Pioneering Lung Cancer Single Cell Research: **4D-Lipidomics**

Dr. Seul Kee Byeon
Mayo Clinic
Rochester, MN

“I am excited that Bruker’s timsTOF Ultra allows me to do single cell lipidomics. I have been able to detect more than 100 species of lipids from an isolated single cell in positive ion mode alone. My next steps include studying heterogeneity at the single cell level, which has not been possible before at this scale.”

A549 lung cancer cells isolated with cellenONE platform (Cellenion) analyzed on the timsTOF Ultra coupled with nanoElute 2 via CSI Ultra source.
"Coupling our well-established micro-flow LC technology via the VIP-HESI source to the timsTOF-HT turned out to be a powerful combination. It enables deep proteome coverage using short gradients thereby linking speed with sensitivity. The development of the 50 µm ESI emitter was key to boost the sensitivity of our micro-flow setup"
Speedy-PASEF (Ralser Group): *Proteomics at Unprecedented Scale*

Ultra-high throughput with 398 samples per day:

- Analytical flow of 500-µL/min flow rate and a 3-min chromatographic gradient, Speedy-PASEF quantified **5,211 proteins from 2µg** of a mammalian cell-line standard at high quantitative accuracy and precision.

300 Hz DDA-PASEF: 4D-Lipidomics
SRM 1950 Plasma lipid extract analyzed in 1.5 min

Precursors containing mobility selected, mass selected, clean MS/MS

=> Up to 300 Precursors fragmented / sec
“From the perspective of a lab heavily invested in cellular signaling processes involved with cancer, MALDI HiPLEX-IHC is a game changer allowing integration of mass spectrometry imaging with cell biology. We will be using this technology for multiomic N-glycan and collagen imaging studies to understand aggressive breast cancers.”
Key Takeaways

1. Revolutionary sensitivity of the timsTOF Ultra will power discovery by identifying lower abundant proteins, with higher coverage using small sample amounts. *Data formats to remain open to facilitate user-driven PASEF optimization.*

2. TIMS technology will continue to evolve further (currently in its 4th generation) influencing high-throughput 4D-proteomics/Lipidomics, PTM analysis & Spatial Multiomics. *Upgradability will always be a top goal whenever possible.*

3. Our M&A partners will continue driving innovation across the proteomics value chain, from sample preparation, separations, data-science and services.

4. Bruker’s MALDI-BioTyper is the world leader in applied clinical proteomics, using proteomic finger-printing for clinical microbiology fast ID.
Transformative insights from discovery to clinic
Biognosys – A Leader in Unbiased Mass Spec-based Proteomics

- 15 Years of proteomics innovation
- 70 Team members across Switzerland, US and the UK
- 30 Granted patents for innovative proteomics software, kits and research services solutions
- 800 Global customers across biotech, pharma, and academia
- 3000 Scientific publications using Biognosys technology

Headquarters and CRO facility in Schlieren, Switzerland

Commercial operations and planned CRO lab in Massachusetts, USA

Joined Bruker Family as of early 2023
Proteomics Enables Multi-Dimensional Understanding of Cellular Function

Genomics

- Genomic building blocks of life

Proteomics

- Expression Level
- Post-Translational Modifications
- Protein Structure / Conformation
- Protein – Protein Interactions

20,000 protein-encoding genes that provides a static view of health risks

>1 million protein variants that are dynamic indicators based on environment and inherited genes

Utility & Actionable Insights to the Phenotype
Poor Understanding of Protein Function Underlies Drug Failure

Lack of Efficacy
- Limited understanding of disease biology: 56%
- Low compound specificity: 28%
- Incomplete understanding of MoA: 7%
- Poorly predictive preclinical models: 5%
- Underperforming biomarkers: 5%

Lack of Safety
- Off-target / Off-site toxicity: 56%
Cracking the Phenotype has the Potential to Revolutionize Precision Medicine

Discover novel drug targets

- FDA Approved drugs
- Potentially druggable targets

Better patient stratification to improve outcomes
Biognosys – Delivering Innovation across the Proteomics Discovery & Process Chain

Samples
- Tissue, FFPE
- Plasma/Serum
- CSF/Urine

Sample Preparation

LC-MS Acquisition

Data Analytics

Data Exploration

© 2023 Bruker
Biognosys leads in deep proteomics
Setting benchmarks since invention of data independent acquisition technology in 2012
Biognosys Enables Access to Leading-edge Proteomics Solutions

For in-house use or as outsourced service

CRO Services
Support in study design and data analytics

Software & Kits
offered with excellent support

Non-Mass Spectrometry Users

Mass Spectrometry Users
Research Services Solutions that Advance and Derisk Drug Discovery

- **DISCOVERY**
  - True Target
    - Novel Drug Target Identification And Validation

- **PRE-CLINICAL**
  - True Discovery
    - Unbiased Biological Insights From Tissue And Biofluids

- **CLINICAL**
  - True Signature
    - Custom Panels For Absolute Protein Quantification
Trusted CRO services
Focus on Pharma and Biotech

85% Pharma & Biotech
60% North America / 40% Europe

> 100 Biotech
> 30 Pharma
> 30 Medical / Academic Institutions
Multiple Biobanks, Diagnostics,
Chemical/Agro, Animal Health

© 2023 Bruker
Biognosys’ Software and Reagent Solutions
Empower Mass Spectrometry Users

Software

- Spectronaut®
- SpectroDive™
- SpectroMine™
- QuiC™

MS Proteomics Signal Extraction, Data Analysis, & Quality Control

Consumables Kits

- Sample Preparation, Quantification, Quality Control

© 2023 Bruker
Biognosys Solutions reach a Broad User Base Across Pharma, Biotech, and Academia

160+ Non-academic Customers

300+ Academic Research Groups

190+ Academic Core Facilities

Industry 24%
Academia 46%
Academic Core Facility 30%

From past 3 years
© 2023 Bruker
Synergies For Proteomics Customer Success

Biognosys’ solutions complement Bruker proteomics ecosystem from sample to insight
Coming soon
Biognosys US proteomics facility powered by Bruker timsTOF

Providing **Targeted and Discovery Services for Proteome Profiling** with Biognosys Standard Methods or Customer Methods
A comprehensive grasp of the phenotype is crucial for unraveling the intricacies of biology.

Proteomics represents a new frontier to provide revolutionary insights for advancing drug discovery.

Biognosys, a leader in proteomics mass spectrometry, enables proteome analysis for transformative drug discovery insights.
BNANO Spatial Biology

Mark R. Munch, Ph. D.
President, Bruker NANO Group
BRUKER INVESTOR DAY

Spatial Biology and Cellular Analysis Built Off Key Core Competency in Fluorescence Imaging

PROJECT ACCELERATE 2.0

Unbiased Proteomics & Multiomics
Biopharma & Applied
Microbiology & Molecular Dx
Spatial Biology, Single-Cell Omics, Cellular Analysis
Assays, Software & Aftermarket
Next-gen Nano & Semi Tools

Core Competency in Fluorescence Imaging

>$70M Revenue 2023

ACCELERATED GROWTH OPPORTUNITIES

NEUROSCIENCE
SPATIAL BIOLOGY
ORGANOID IMAGING
EXTRACELLULAR VESICLES
IMMUNOLOGY
BRUKER INVESTOR DAY

Spatial Biology and Cellular Analysis Built Off Key Core Competency in Fluorescence Imaging

PROJECT ACCELERATE 2.0

Unbiased Proteomics & Multiomics
Biopharma & Applied
Assays, Software & Aftermarket
Next-gen Nano & Semi Tools
Spatial Biology, Single-Cell Omics, Cellular Analysis

ACCELERATED GROWTH OPPORTUNITIES

NEUROSCIENCE
SPATIAL BIOLOGY
EXTRACELLULAR VESICLES
IMMUNOLOGY
ORGANOID IMAGING

Core Competency in Fluorescence Imaging

Multiphoton Microscopy
Super Resolution Microscopy
Light Sheet Microscopy
MiniScope 1P Microscopy
Spatial Biology and Cellular Analysis Built Off Key Core Competency in Fluorescence Imaging
Spatial Biology and Cellular Analysis Built Off Key Core Competency in Fluorescence Imaging

- Spatial Biology
- Extracellular Vesicles
- Immunology
- Neuroscience
- Organoid Imaging

Core Competency in Fluorescence Imaging
BRUKER INVESTOR DAY
Spatial Biology and Cellular Analysis Built Off Key Core Competency in Fluorescence Imaging

Core Competency in Fluorescence Imaging

SPATIAL BIOLOGY
Canopy CellScape Tissue and Cell Suspension Imaging

EXTRACELLULAR VESICLES
Vutara Super-Resolution Microscopy

IMMUNOLOGY

NEUROSCIENCE
Ultima 2-Photon Microscopy
Inscopix 1-P Microscopy

ORGANOID IMAGING
Luxendo Light-Sheet Microscopy
Spatial Biology Built Off Key Core Competencies

PROJECT ACCELERATE 2.0

Unbiased Proteomics & Multiomics
Biopharma & Applied
Assays, Software & Aftermarket
Next-gen Nano & Semi Tools
Spatial Biology, Single-Cell Omics, Cellular Analysis
Microbiology & Molecular Dx

ACCELERATED GROWTH OPPORTUNITIES

NEUROSCIENCE
ORGANOID IMAGING
EXTRACELLULAR VESICLES
IMMUNOLOGY

Core Competency in Fluorescence Imaging
Market Segmentation in Spatial Biology

- **Discovery Research (Academic)**
- **Translational Research**
- **Clinical Dx**

**Select Bruker Portfolio**

- **Canopy Multiplexed Proteomics**
- **CellScape**
- **Mass Spec Imaging**
  - **timesTOF Flex**
- **Acuity Spatial Genomics jebFISH**
  - **PaintScape**

**High PLEX**
- Transcriptomics + Proteomics + Other Multiomics

**Low PLEX**
- Transcriptomics + Proteomics

**Canopy spans across multiple spatial segments**
Why is Spatial Important – Provides *in situ* Positional Context of Cells in Tissue
Spatial Biology provides new insights in how to diagnose and treat disease

What are and where are the cell types in the tumor microenvironment (TME)?

What are the sub-types of these cell types?

What does the immune cell infiltration look like in the TME?

What is happening at the tumor-immune system interface?

The Tumor Microenvironment

Biology is Spatial – There is high value in its teachings.
Biology is Complex – Our understanding is just beginning.

What is the relationship between the cells?

Can we understand the cell-cell communication networks?

What are the key roles of these cells?
What are they doing?

Can we develop better diagnostics?
Can we design better therapies?

Artistic rendering using BioRender.com
Example of Bruker Innovation Fueling Growth
The Transformation of Canopy Biosciences to a performance leader in Spatial Biology

**Bruker Canopy Biosciences**
Differentiated quantitative performance in spatial biology

**CellScape platform**

- **CANCER & IMMUNO-ONCOLOGY**
- **IMMUNOLOGY**
- **NEUROBIOLOGY**
Canopy was a CRO

- Had perfected a protocol for cyclic, multiplexed immunofluorescence (mIF)
- Had a proprietary methodology and algorithm for 8-log, high dynamic range (HDR) detection
- Standardized the protocol to provide robust services

Was lacking:

- An instrument
- Standard panels/kits

We saw an opportunity to add a pivot to create a play in spatial biology with:

- Best-in-class, high resolution, multiplexed instrument optimized for these protocols
- Standard panels/kits for different sub-applications which leverage the CRO experience into ‘hardened’ protocols
- Simultaneously operating a successful services CRO in parallel which continually builds our competence

Result

A differentiated, quantitative platform with leading sensitivity and precision of quantitation
Canopy CellScape
The reality of getting to differentiated, quantitative results at high throughput with low hassle

Key Features of Canopy Cellscape

- Multiple industry-leading performance advancements
  - HIGH OPTICAL RESOLUTION
  - HIGH DYNAMIC RANGE
  - VERY HIGH MULTIPLEX
  - MULTI-SAMPLE RUNS
  - WHOLE SLIDE IMAGING
  - VALIDATED PANELS
  - WALKAWAY AUTOMATION
  - FLEXIBLE, EASY PROTOCOLS

The Differentiating Truth That Matters

- Differentiated, Quantitative Performance
- Straightforward, Reliable Technique
- Fast Time to Result, High Throughput
- High-Plex Capability Actually Realized

Why You Should Really Care

- See all the spatial neighborhood/Phenotype completely
- Get productive sooner without lengthy assay development
- Confidence to get results at whatever plex and marker choices you want
Why is this **differentiated, quantitative** performance important?

**Highest Optical Resolution & True Single Cell Resolution**

- **182 nm/pixel**
- Proprietary HDR image acquisition pipeline enables detection of low and high expression
- Proprietary algorithms for quantitative interpretation

**High Dynamic Range (HDR) & Quantitative AI**

- 8-log dynamic range

**Quantitatively phenotype all cells**

- Classify all cell types in the continuum of cell expression levels

- See the whole neighborhood... do you want to see just some of the neighborhood?
  - Cells appear in very different abundance levels
  - Each cell has a role in the biology / communication pathways in the tissue

- Accurate phenotyping and segmentation
  - Phenotype is a continuum (it is in degrees) ... with our high resolution and high dynamic range we see the subtypes and gradations in the subtypes

**Maximize the cells you can see** and maximize what you can see in **degrees of expression**.
Accurate and quantitative cell phenotyping with Canopy CellScape's high resolution, high dynamic range, and highplex
Accurate and quantitative cell phenotyping with Canopy CellScape’s high resolution, high dynamic range, and high plex
Complete Phenotyping with Absolute Quantification of Cell Populations

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Spleen (Leukemia)</th>
<th>Femur (Leukemia)</th>
<th>Spleen (Control)</th>
<th>Femur (Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chip ID</td>
<td>M1</td>
<td>M2</td>
<td>M3</td>
<td>M4</td>
</tr>
<tr>
<td>Target population</td>
<td>Cell Count</td>
<td>% of Leukocytes</td>
<td>% of Parent Population</td>
<td>Cell Count</td>
</tr>
<tr>
<td>All cells</td>
<td>144,805</td>
<td>100.00%</td>
<td>81.15%</td>
<td>59,756</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>117,514</td>
<td>100.00%</td>
<td>81.15%</td>
<td>17,521</td>
</tr>
<tr>
<td>T cells</td>
<td>3,719</td>
<td>3.16%</td>
<td>3.16%</td>
<td>262</td>
</tr>
<tr>
<td>Helper T cells</td>
<td>1428</td>
<td>1.22%</td>
<td>38.40%</td>
<td>65</td>
</tr>
<tr>
<td>Cytotoxic T cells</td>
<td>251</td>
<td>0.21%</td>
<td>6.75%</td>
<td>17</td>
</tr>
<tr>
<td>Regulatory T-cells</td>
<td>109</td>
<td>0.09%</td>
<td>7.63%</td>
<td>3</td>
</tr>
<tr>
<td>Activated T cells</td>
<td>1,207</td>
<td>1.03%</td>
<td>32.45%</td>
<td>178</td>
</tr>
<tr>
<td>NKT cells</td>
<td>2,456</td>
<td>2.09%</td>
<td>2.09%</td>
<td>240</td>
</tr>
<tr>
<td>NK cells</td>
<td>1,617</td>
<td>1.38%</td>
<td>1.38%</td>
<td>126</td>
</tr>
<tr>
<td>Activated NK cells</td>
<td>592</td>
<td>0.50%</td>
<td>36.61%</td>
<td>100</td>
</tr>
<tr>
<td>B cells</td>
<td>14,732</td>
<td>12.54%</td>
<td>12.54%</td>
<td>4,738</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>8,225</td>
<td>7.00%</td>
<td>7.00%</td>
<td>439</td>
</tr>
<tr>
<td>Monocytes/macrophages</td>
<td>15,074</td>
<td>12.83%</td>
<td>12.83%</td>
<td>485</td>
</tr>
<tr>
<td>M2 macrophages</td>
<td>3,229</td>
<td>2.75%</td>
<td>21.42%</td>
<td>120</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>1,242</td>
<td>1.06%</td>
<td>1.06%</td>
<td>1,702</td>
</tr>
<tr>
<td>Proliferating immune cells</td>
<td>6,918</td>
<td>5.89%</td>
<td>5.89%</td>
<td>3,358</td>
</tr>
</tbody>
</table>
High plex and single cell resolution enable quantitative subtyping of immune cells in breast cancer

Single cell resolution and high dynamic range are required for quantitative phenotyping, and CellScape is the only platform with that fidelity combination.
CellScape is the only platform capable of producing **bivariate gating** population clustering, which picks up cell types our competitors miss.

**Bivariate gating** requires **high resolution** and **high dynamic range** images.
Fast Time to Result with High Throughput, Whole Slide Imaging
We have best-in-class throughput for plex > 8

- Largest FOV at High Spatial Resolution
  - Don’t get fooled by small FOV’s and just select regions – Tissue neighborhoods are heterogeneous (that’s the whole point of Spatial)

- Can Fly Through Tissues – 100,000’s of Cells
  - Sample very quickly across different regions or the whole tissue
  - Capable of four samples per run

Rapid analysis of whole tissue sections with larger FOVs.
Single FOVs of 0.81mm² and 3.4mm² (comparison standard is 0.39mm²)
Walk-away automation
Straightforward, Reliable, Flexible Technique

- Primary, monoclonal antibodies
  - High specificity
  - Don’t get fooled by cross reactivity of a lot of secondary antibodies

- No custom conjugations that can disrupt binding and affinity of the Antibody Clones you know

- Faster antibody marker validation

Advantage of biomarker flexibility and customization — Use the clones you know
Primary monoclonal antibodies for high specificity
System demonstrated with standard RNAScope markers as well

The ease of open source reagents
Leads to being highly productive sooner.
**Actual** High-Plex while keeping the integrity of the sample

- No harsh washes with Canopy platform
  Think of the force and what it takes for the unbinding of readout probes in competitor systems (chemical interactions)
  - What heat does
  - What harsh chemicals can do to precious tissue
- Can even reinterrogate sample after 2-3 years
- All done with walkaway automation

**Canopy CellScape Protocol**

- Stain
- Image
- Erase
- Reinterrogate

Can *actually* realize High-Plex since protocol maintains sample integrity / gentler on precious tissue samples
Human breast carcinoma
(100-plex study)

**SELECT CELL TYPES IDENTIFIED**
- **T cells** | CD8+ and CD4+
- **B cells** | CD20+
- **NK cells** | CD56+
- **Epithelial cells** | pan-Cytokeratin+
- **Tumor cells** | CD340+ (Her2)

Comprehensive study of breast tissue with **100 markers**...able to perform **high-plex** with **quantitative phenotyping** across a **continuum** of cell types.

Image on the right shows the single FOV below.
Canopy CellScape | for spatial biology analysis
The differentiating truth that matters:

Differentiated, Quantitative Performance
Straightforward, Reliable Technique
Fast Time to Result, High Throughput
High-Plex Capability Actually Realized
Neuroscience

Mark R. Munch, Ph. D.
President, Bruker NANO Group
Spatial Biology Built Off Key Core Competencies

PROJECT ACCELERATE 2.0

- Unbiased Proteomics & Multiomics
- Biopharma & Applied
- Assays, Software & Aftermarket
- Next-gen Nano & Semi Tools
- Spatial Biology, Single-Cell Omics, Cellular Analysis
- Microbiology & Molecular Dx

ACCELERATED GROWTH OPPORTUNITIES

- Neuroscience
- Spatial Biology
- Organoid Imaging
- Extracellular Vesicles
- Immunology

Core Competency in Fluorescence Imaging
### The Importance of Neuroscience Research

**Brain Disorders: An Escalating Public Health Crisis**

<table>
<thead>
<tr>
<th>Prevalence</th>
<th>Global Economic Cost</th>
<th>Brain Disorders</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.5% of people living with a brain disorder globally / 25% suffer from at least one brain disorder during their lifetime</td>
<td>The global economic burden of brain disorders is $3 Trillion and projected to rise to $6 Trillion by 2030</td>
<td>There are 600 types of neurological, psychiatric, and sensory disorders</td>
<td>NIH Neuroscience funding in 2023: $11.5B</td>
</tr>
</tbody>
</table>

- **Prevalence**
  - 12.5% of people living with a brain disorder globally / 25% suffer from at least one brain disorder during their lifetime

- **Global Economic Cost**
  - The global economic burden of brain disorders is $3 Trillion and projected to rise to $6 Trillion by 2030

- **Brain Disorders**
  - There are 600 types of neurological, psychiatric, and sensory disorders

- **Dementia**
  - 47.5 million people globally with dementia with 7.7 million new cases every year

- **R&D Spend**
  - Estimated total Neuro / CNS therapeutics R&D spend in 2027

- **Funding**
  - NIH Neuroscience funding in 2023: $11.5B

- **Economic Cost**
  - $3T

- **Prevalence**
  - $150B-$200B

- **R&D Spend**
  - $11.5B
Fluorescence Microscopy Application Areas In Neuroscience

- Whole brain imaging
  - Luxendo Light-Sheet Microscopy

- Brain organoids
  - Luxendo Light-Sheet Microscopy
  - Ultima 2-Photon Microscopy

- Brain circuit mapping and manipulation
  - Ultima 2-Photon Microscopy
  - InscoPix 1-P Microscopy

- Spatial phenotyping / Spatial biology
  - Canopy CellScape Tissue Imaging

- Molecular signaling / synaptic junctions
  - Vutara Super-Resolution Microscopy
Medium-Term Financial Outlook – 2023 to 2026

Gerald Herman
Executive Vice President & Chief Financial Officer
June 15, 2023
Reminder: FY 2023 Outlook
Guidance (Unchanged from May 4, 2023)

<table>
<thead>
<tr>
<th>FY 2023 Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue (in $B)</td>
</tr>
<tr>
<td>Reported Growth</td>
</tr>
<tr>
<td>Organic Growth</td>
</tr>
<tr>
<td>Constant Currency Growth</td>
</tr>
<tr>
<td>Non-GAAP EPS</td>
</tr>
<tr>
<td>Non-GAAP EPS Growth</td>
</tr>
</tbody>
</table>

FY 2023 Non-GAAP Assumptions (as of May 4, 2023)

- Operating profit growth 8%-10%;
- Operating margin decline ~70 bps
  - Accelerating R&D to ~10% of revenue, with focus on proteomics and spatial biology
  - Organic operating margin increase ~50 bps
  - Transitory 2023 headwind of ~120 bps to operating margin from FX and acquisitions
- Effective tax rate: 28%
- CAPEX: $130M
- FX assumptions (rates as of March 31, 2023):
  - EUR = 1.086 USD; CHF = 1.094 USD; Yen = 0.0075 USD
Transformation of Bruker Revenue Portfolio - *Project Accelerate 2.0*

2022 BSI\(^{(1)}\) END MARKET MIX

- BioPharma: 16%
- Industrial & Green Tech: 21%
- Microbiology: 10%
- Semi-Metrology: 4%
- Applied/Food: 10%
- Academic & Government: 39%

Repositioned for Strong Secular Trends, Diversified Markets Mitigate Risk

2022 BRUKER PA 2.0 SHARE

- Bruker Core: 56%
- PA 2.0: 30%

Growing *Project Accelerate 2.0* Contribution Drives Growth & Margins

2022 BSI\(^{(1)}\) GEOGRAPHIC MIX

- US: 36%
- Europe: 34%
- Rest of the World: 30%

More Balanced Geographic Mix, Rapid Growth in US

---

(1) Bruker Scientific Instruments (BSI) revenue reflects sum of BSI BioSpin, BSI CALID and BSI Nano Segments
Organic Revenue - *Significant Growth Acceleration 2021 - 2023*

Clear Evidence of Sustained *Project Accelerate 2.0* – driven organic revenue growth acceleration

---

**ORGANIC REVENUE GROWTH** *(1)*

- 2017: 3.6%
- 2018: 4.3%
- 2019: 5.7%
- 2020: -6.0%
- 2021: 19.1%
- 2022: 10.2%
- 2023G: 10.0%

---

(1) Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth at the end of presentation.
(2) FY2023 guidance figures are mid-point of guidance range.
Increasing Margins and Earnings - *Driving Shareholder Value*

**NON-GAAP\(^{(1)}\) GROSS MARGIN 2017-2023G\(^{(2)}\)**

- **Strong Gross Margin Expansion**
  - BSI Gross Margin >55% in FY2023G

**NON-GAAP\(^{(1)}\) OPERATING MARGIN 2017-2023G\(^{(2)}\)**

- **Continued Operating Margin Expansion**
  - 2023G R&D OPEX ~10%

**NON-GAAP\(^{(1)}\) EPS 2017-2023G\(^{(2)}\)**

- **2023G EPS Doubles vs. 2017**
  - RoIC Sustained at >20%

---

\(\text{(1)}\) Reconciliations of non-GAAP gross margin, operating margin and EPS to most directly comparable GAAP measures at end of presentation.

\(\text{(2)}\) FY2023 guidance figures are mid-point of guidance range. FY2023G includes 120 bps headwind from FX and M&A.
Medium Term Outlook - **Key Drivers of Higher Revenue Growth**

**Project Accelerate 2.0**

- **Proteomics**
  - **Expected Organic Revenue Growth ('24-'26)**
  - **$2.86B(1) Bruker 2023G Revenue**
  - **$1.6B**
  - **$1.3B**

- **Spatial Biology**

- **Microbiology & MDx**

- **Biopharma & Applied**

- **Next-gen Nano & Semi Metrology**

- **Aftermarket, Consumables & Software**

- **Bruker Core**

---

(1) Mid-point of 2023G revenue guidance range
(2) MSD – mid-single digits, HSD - high single digits, DD – double digits % growth
Key Strategic Pillar - *Operational Excellence & Productivity Investments*

- Excellence in Operations, Commercial and Product R&D
- Driving growth, expanding gross and operating margins
- Proven progress and foundation for further investments and sustainable growth
- Strong focus on OCF and FCF generation post supply chain crisis
R&D Investment - *Advancing Purposeful Innovation*

Industry-leading R&D investment in *Project Accelerate 2.0* initiatives

- Drives product innovation and accelerates revenue growth
- Focus on fast growing opportunities in **proteomics & spatial biology**

**Solution Leadership & Deep Biology and Disease Applications Expertise**

- **timsTOF®** unbiased, deep 4D-Proteomics
  - 4D-Epideproteomics
  - 4D-Lipidomics
  - Tissue SpatialOMx
  - Single Cell Proteomics
  - Cancer Research
  - Neuroscience R&D Tools

- **Cellular Analysis**
  - Canopy Spatial & Single-Cell Omics
  - Acuity Spatial 3D Genomics

- **MALDI Biotyper**
  - MBT Sepsityper IVD
  - LiquidArray PCR Panels

- **GHz NMR Functional Structural Biology**
  - Translational Phenomics by NMR and MS

- **NMR and MS**: Unique **Biopharma Solutions for Biologics**

- **Leading Nano Tools**: Materials Research, Semi Metrology & Microelectronics
  - **GreenTech Tools**
Free Cash Flow (FCF) – Investing in Accelerating Growth and Margin Expansion

- Capital investment to drive increased capacity for next decade of high growth
- Increased investment to enhance productivity and improve gross margins through operational excellence
Innovation driving Sustainability - 2023 Sustainability Report

Expanded ESG report published early this week

**Environmental**
- Active environmental impact management
  - 39% renewables of total energy consumed
  - Additional sustainable energy initiatives underway
  - >65% of waste recycled or reused

**Social**
- Dynamic, diverse, empathetic and inclusive high-performance culture
  - Solid employee development programs
  - Exemplary employee and safety record
  - >55% of employees eligible for bonus

**Governance**
- High standards or corporate governance
  - Strong corporate compliance structure with proactive, diverse Board
  - Governance standards apply to our supplier network and ecosystem
Capital Deployment Strategy - **Strong ROIC** \(^{(1)}\) **Consistently >20%**

OUTSTANDING ROIC PERFORMANCE IS CLEAR EVIDENCE OF **DISCIPLINED ENTREPRENEURIALISM**

<table>
<thead>
<tr>
<th>Year</th>
<th>ROIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>27.3%</td>
</tr>
<tr>
<td>2018</td>
<td>27.0%</td>
</tr>
<tr>
<td>2019</td>
<td>26.5%</td>
</tr>
<tr>
<td>2020</td>
<td>21.2%</td>
</tr>
<tr>
<td>2021</td>
<td>27.6%</td>
</tr>
<tr>
<td>2022</td>
<td>24.3%</td>
</tr>
</tbody>
</table>

**Invest in Profitable Growth**
- Above peer R&D investment ~10%
- Commercial investments in key **Project Accelerate 2.0** initiatives
- CAPEX investment in capacity expansion and productivity
- Strategic and bolt-on M&A

**Sustain Financial Flexibility**
- Strong, flexible balance sheet
- Conservative debt levels
- Prudent **Margin of Safety**
- S-3 shelf for strategic flexibility

**Return Capital to Shareholders**
- Annual dividend $0.20 per share, expected to increase to $0.24 per share in 2025, paid quarterly
- Share repurchase authorization of up to $500M over 2 years

---

\(^{(1)}\) Return on Invested Capital (ROIC) is a non-GAAP measure. A reconciliation of this measure to the most directly comparable GAAP measure is at the end of this presentation.
Medium-Term Outlook 2023 - 2026

Expect organic revenue growth 200-300 bps above market (4-6%) Towards $3.5B revenue, $3.50 non-GAAP EPS - and beyond

ORGANIC DRIVERS & METRICS

- HSD-DD Project Accelerate 2.0 growth
- Organic revenue growth 200-300 bps above market
- DD growth in non-GAAP Operating Profit & EPS
- Accelerating OCF and FCF generation

STRATEGIC OPTIONALITY

- Strategic and bolt-on M&A
- Strategic M&S and R&D investments
- Share repurchases
- Continued high RoIC

(1) FY2023 guidance figures are mid-point of guidance range
Medium-Term Financial Outlook for FY2026

- **Revenue:** $3.4B - $3.6B
  - organic revenue growth 200-300 bps above market

- **BSI Gross Margin:** >56%

- **OPM:** 21.0% - 22.0%
  - with R&D opex investment at ~10% of revenues

- **Non-GAAP EPS:** $3.40 - $3.70
  - tax rate below 27%
  - accelerating OCF and FCF generation
  - continued high RoIC
Appendix
Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth

<table>
<thead>
<tr>
<th>[$ m]</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP revenue as of prior comparable period</td>
<td>$1,611.3</td>
<td>$1,765.9</td>
<td>$1,895.6</td>
<td>$2,072.6</td>
<td>$1,987.5</td>
<td>$2,417.9</td>
</tr>
</tbody>
</table>

Non-GAAP adjustments:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisitions and divestitures</td>
<td>77.2</td>
<td>28.2</td>
<td>118.4</td>
<td>10.5</td>
<td>8.1</td>
<td>34.3</td>
</tr>
<tr>
<td>Currency</td>
<td>19.6</td>
<td>25.5</td>
<td>(50.3)</td>
<td>29.4</td>
<td>43.3</td>
<td>(168.0)</td>
</tr>
<tr>
<td>Organic</td>
<td>57.8</td>
<td>76.0</td>
<td>108.9</td>
<td>(125.0)</td>
<td>379.0</td>
<td>246.5</td>
</tr>
<tr>
<td>Total non-GAAP adjustments</td>
<td>154.6</td>
<td>129.7</td>
<td>177.0</td>
<td>(85.1)</td>
<td>430.4</td>
<td>112.8</td>
</tr>
</tbody>
</table>

Non-GAAP revenue

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,765.9</td>
<td>$1,895.6</td>
<td>$2,072.6</td>
<td>$1,987.5</td>
<td>$2,417.9</td>
<td>$2,530.7</td>
<td></td>
</tr>
</tbody>
</table>

Revenue growth

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.6%</td>
<td>7.3%</td>
<td>9.3%</td>
<td>-4.1%</td>
<td>21.7%</td>
<td>4.7%</td>
<td></td>
</tr>
</tbody>
</table>

Organic revenue growth

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.6%</td>
<td>4.3%</td>
<td>5.7%</td>
<td>-6.0%</td>
<td>19.1%</td>
<td>10.2%</td>
<td></td>
</tr>
</tbody>
</table>
Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS

<table>
<thead>
<tr>
<th>($ m, except per share amounts)</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP operating income*</td>
<td>$219.5</td>
<td>$262.4</td>
<td>$300.9</td>
<td>$248.3</td>
<td>$413.3</td>
<td>$432.7</td>
</tr>
<tr>
<td>Non-GAAP adjustments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring costs</td>
<td>16.2</td>
<td>9.4</td>
<td>1.4</td>
<td>15.8</td>
<td>8.2</td>
<td>4.8</td>
</tr>
<tr>
<td>Acquisition-related costs</td>
<td>10.2</td>
<td>7.3</td>
<td>16.8</td>
<td>3.2</td>
<td>6.9</td>
<td>19.7</td>
</tr>
<tr>
<td>Purchased intangible amortization</td>
<td>29.6</td>
<td>28.9</td>
<td>38.3</td>
<td>35.7</td>
<td>37.4</td>
<td>37.1</td>
</tr>
<tr>
<td>Other costs</td>
<td>5.4</td>
<td>9.9</td>
<td>6.6</td>
<td>14.2</td>
<td>4.4</td>
<td>11.3</td>
</tr>
<tr>
<td><strong>Total non-GAAP adjustments:</strong></td>
<td>61.4</td>
<td>55.5</td>
<td>63.1</td>
<td>68.9</td>
<td>56.9</td>
<td>72.9</td>
</tr>
<tr>
<td>Non-GAAP operating income</td>
<td>280.9</td>
<td>317.9</td>
<td>364.0</td>
<td>317.2</td>
<td>470.2</td>
<td>505.6</td>
</tr>
<tr>
<td>Non-GAAP operating margin</td>
<td>15.9%</td>
<td>16.8%</td>
<td>17.6%</td>
<td>16.0%</td>
<td>19.4%</td>
<td>20.0%</td>
</tr>
<tr>
<td>Non-GAAP interest &amp; other expense, net</td>
<td>(22.3)</td>
<td>(17.7)</td>
<td>(20.5)</td>
<td>(22.5)</td>
<td>(19.7)</td>
<td>(20.4)</td>
</tr>
<tr>
<td>Non-GAAP profit before tax</td>
<td>258.6</td>
<td>300.2</td>
<td>343.5</td>
<td>294.7</td>
<td>450.5</td>
<td>485.2</td>
</tr>
<tr>
<td>Non-GAAP income tax provision</td>
<td>(64.7)</td>
<td>(78.5)</td>
<td>(96.6)</td>
<td>(82.9)</td>
<td>(126.1)</td>
<td>(134.4)</td>
</tr>
<tr>
<td>Minority interest</td>
<td>(1.7)</td>
<td>(1.3)</td>
<td>(0.8)</td>
<td>(3.6)</td>
<td>(3.5)</td>
<td>(1.9)</td>
</tr>
<tr>
<td><strong>Non-GAAP net income attributable to Bruker</strong></td>
<td>$192.2</td>
<td>$220.4</td>
<td>$246.1</td>
<td>$208.2</td>
<td>$320.9</td>
<td>$348.9</td>
</tr>
<tr>
<td>Weighted average shares outstanding (diluted)</td>
<td>159.1</td>
<td>157.2</td>
<td>156.6</td>
<td>154.6</td>
<td>152.9</td>
<td>149.4</td>
</tr>
<tr>
<td><strong>Non-GAAP earnings per share</strong></td>
<td>$1.21</td>
<td>$1.40</td>
<td>$1.57</td>
<td>$1.35</td>
<td>$2.10</td>
<td>$2.34</td>
</tr>
</tbody>
</table>

* Attributable to Bruker
## Reconciliation of Non-GAAP Gross Profit

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GAAP gross profit</strong></td>
<td>816.0</td>
<td>900.0</td>
<td>995.3</td>
<td>939.8</td>
<td>1,209.6</td>
<td>1,305.7</td>
</tr>
<tr>
<td><strong>Non-GAAP adjustments:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring costs</td>
<td>5.6</td>
<td>2.6</td>
<td>5.2</td>
<td>3.8</td>
<td>3.4</td>
<td>0.9</td>
</tr>
<tr>
<td>Acquisition-related costs</td>
<td>5.7</td>
<td>3.9</td>
<td>12.2</td>
<td>0.8</td>
<td>0.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Purchased intangible amortization</td>
<td>24.0</td>
<td>21.6</td>
<td>23.5</td>
<td>19.9</td>
<td>20.2</td>
<td>18.3</td>
</tr>
<tr>
<td>Other costs</td>
<td>0.8</td>
<td>0.6</td>
<td>0.8</td>
<td>3.7</td>
<td>1.1</td>
<td>4.8</td>
</tr>
<tr>
<td><strong>Non-GAAP gross profit</strong></td>
<td><strong>852.1</strong></td>
<td><strong>928.7</strong></td>
<td><strong>1,037.0</strong></td>
<td><strong>968.0</strong></td>
<td><strong>1,235.0</strong></td>
<td><strong>1,330.1</strong></td>
</tr>
<tr>
<td><strong>Non-GAAP gross margin</strong></td>
<td><strong>48.3%</strong></td>
<td><strong>49.0%</strong></td>
<td><strong>50.0%</strong></td>
<td><strong>48.7%</strong></td>
<td><strong>51.1%</strong></td>
<td><strong>52.6%</strong></td>
</tr>
</tbody>
</table>
# Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net

<table>
<thead>
<tr>
<th>[$ m]</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP Interest &amp; Other Income (Expense), net</td>
<td>$(21.7)</td>
<td>$(17.7)</td>
<td>$(20.5)</td>
<td>$(22.5)</td>
<td>$(19.7)</td>
<td>$(20.4)</td>
</tr>
<tr>
<td>Non-GAAP Adjustments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sale of Product Line</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bargain Purchase Gain</td>
<td>-</td>
<td>(0.6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pension Settlement Charge</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-GAAP Interest &amp; Other Income (Expense), net</td>
<td>$(22.3)</td>
<td>$(17.7)</td>
<td>$(20.5)</td>
<td>$(22.5)</td>
<td>$(19.7)</td>
<td>$(20.4)</td>
</tr>
</tbody>
</table>
Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP Earnings Per Share (Diluted)</td>
<td>$0.49</td>
<td>$1.14</td>
<td>$1.26</td>
<td>$1.02</td>
<td>$1.81</td>
<td>$1.99</td>
</tr>
<tr>
<td>Non-GAAP adjustments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring costs</td>
<td>0.10</td>
<td>0.06</td>
<td>0.01</td>
<td>0.10</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>Acquisition-related costs</td>
<td>0.06</td>
<td>0.05</td>
<td>0.11</td>
<td>0.02</td>
<td>0.05</td>
<td>0.13</td>
</tr>
<tr>
<td>Purchased intangible amortization</td>
<td>0.19</td>
<td>0.18</td>
<td>0.24</td>
<td>0.23</td>
<td>0.24</td>
<td>0.25</td>
</tr>
<tr>
<td>Other costs</td>
<td>0.04</td>
<td>0.06</td>
<td>0.04</td>
<td>0.09</td>
<td>0.04</td>
<td>0.06</td>
</tr>
<tr>
<td>Sale of product line</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pension settlement charge</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bargain purchase gain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Income tax rate differential</td>
<td>0.33</td>
<td>(0.09)</td>
<td>(0.09)</td>
<td>(0.11)</td>
<td>(0.09)</td>
<td>(0.12)</td>
</tr>
<tr>
<td>Total Non-GAAP adjustments:</td>
<td>0.72</td>
<td>0.26</td>
<td>0.31</td>
<td>0.33</td>
<td>0.29</td>
<td>0.35</td>
</tr>
<tr>
<td>Non-GAAP earnings per share (diluted)</td>
<td>$1.21</td>
<td>$1.40</td>
<td>$1.57</td>
<td>$1.35</td>
<td>$2.10</td>
<td>$2.34</td>
</tr>
</tbody>
</table>
### Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow

<table>
<thead>
<tr>
<th>[$\text{m}$]</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP operating cash flow</td>
<td>$154.4</td>
<td>$239.7</td>
<td>$213.4</td>
<td>$332.2</td>
<td>$282.4</td>
<td>$274.4</td>
</tr>
<tr>
<td>Non-GAAP Adjustments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of property, plant and equipment</td>
<td>(43.7)</td>
<td>(49.2)</td>
<td>(73.0)</td>
<td>(97.2)</td>
<td>(92.0)</td>
<td>(129.2)</td>
</tr>
<tr>
<td>Non-GAAP Free Cash Flow</td>
<td>$110.7</td>
<td>$190.5</td>
<td>$140.4</td>
<td>$235.0</td>
<td>$190.4</td>
<td>$145.2</td>
</tr>
</tbody>
</table>
Reconciliation of Non-GAAP Return on Invested Capital (ROIC)

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-GAAP operating income*</td>
<td>$280.9</td>
<td>$317.9</td>
<td>$364.0</td>
<td>$317.2</td>
<td>$470.2</td>
<td>$505.6</td>
</tr>
<tr>
<td>Less: Non-GAAP Income Tax Provision</td>
<td>(64.7)</td>
<td>(78.5)</td>
<td>(96.6)</td>
<td>(82.9)</td>
<td>(126.1)</td>
<td>(134.4)</td>
</tr>
<tr>
<td>Non-GAAP operating income after tax</td>
<td>$216.2</td>
<td>$239.4</td>
<td>$267.4</td>
<td>$234.3</td>
<td>$344.1</td>
<td>$371.2</td>
</tr>
</tbody>
</table>

Average total invested capital:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average long-term debt</td>
<td>$403.6</td>
<td>$369.1</td>
<td>$567.7</td>
<td>$827.6</td>
<td>$1,034.3</td>
<td>$1,213.0</td>
</tr>
<tr>
<td>Average current portion of long-term debt</td>
<td>10.1</td>
<td>9.3</td>
<td>9.5</td>
<td>1.4</td>
<td>57.3</td>
<td>65.6</td>
</tr>
<tr>
<td>Average shareholders’ equity</td>
<td>713.3</td>
<td>830.6</td>
<td>933.0</td>
<td>956.3</td>
<td>1,029.6</td>
<td>1,108.3</td>
</tr>
<tr>
<td>Less average cash and cash equivalents</td>
<td>333.7</td>
<td>323.7</td>
<td>500.4</td>
<td>680.1</td>
<td>875.0</td>
<td>856.9</td>
</tr>
<tr>
<td>Total average invested capital</td>
<td>$793.3</td>
<td>$885.3</td>
<td>$1,009.8</td>
<td>$1,105.2</td>
<td>$1,246.2</td>
<td>$1,530.0</td>
</tr>
<tr>
<td>Return on Invested Capital (ROIC)</td>
<td>27.3%</td>
<td>27.0%</td>
<td>26.5%</td>
<td>21.2%</td>
<td>27.6%</td>
<td>24.3%</td>
</tr>
</tbody>
</table>

* Non-GAAP operating income reconciliation is provided on slide 18
Non-GAAP Financial Measures

Additional information regarding our use of non-GAAP financial measures, including how we define and calculate such non-GAAP financial measures, is included on page 37 under Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 1, 2023.

With respect to our outlook for 2023 non-GAAP organic revenue, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue, operating margin, tax rate and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future period operating margins, EPS and tax rate calculated and presented in accordance with GAAP.
Presenter Bios
Frank H. Laukien, Ph.D.
Chairman, President and CEO, Bruker Corporation

- Chairman, President and CEO of Bruker, and Bruker’s largest stockholder
- Leading Project Accelerate & Operational Excellence, and unique Bruker culture
- Brings perspective of significant stakeholder with in-depth knowledge of all aspects of our company and markets, and a long history of leading innovation and profitable growth
- Provides extensive executive experience in organizational management, strategic planning, finance, global business development and life science tools markets, as well as scientific background for deep understanding of key technologies, markets and industry dynamics.

EDUCATION & ACADEMIC
- MIT B.Sc. Physics, Harvard Ph.D. Chemical Physics
- Visiting Scholar, Harvard, Dept. of Chemistry & Chemical Biology, Origins of Life Initiative
- Author of book on organismal & cancer evolution: *Active Biological Evolution*
- Visiting Committee, MIT Dept. of Chemistry
- SAB ANPC Perth, SAB Cell Hospital Berlin

OTHER ACTIVITIES
- Senator of acatech, the German National Academy of Science and Engineering
- Co-Founder and Immediate Past Chair of AACR Cancer Evolution Working Group
- Director of ALDA
- Executive Chair, Gauss Fusion Initiative
EXECUTIVE BIO

Mark R. Munch, Ph.D.
President, Bruker NANOGroup and Corporate Executive Vice President

- President, Bruker Nano Group, with responsibility for the Group’s global operations.
- Executive Vice President of Bruker Corporation, focus on Bruker Management Processes and Global IT/ERP oversight.
- Over 32 years managing significant businesses of multi-national corporations.
- Strong track record of building high-growth, high-margin organizations that foster organizational, operational, and commercial excellence. Deep expertise in strategy, product development, mergers and acquisitions, sales and marketing, and global manufacturing.

PRIOR TO BRUKER
- Executive Vice President, Veeco Instruments, Inc.
- Senior Vice President, Coherent, Inc.
- President and Chief Executive Officer, Cooligy, Inc. (became a subsidiary of Emerson Electric)
- VP/GM, CTO Photonics, Corning, Inc.
- CTO, VP/GM, Tyco International
- Various executive positions, Raychem Corporation

EDUCATION
- BS, Chemical Engineering, Univ. of Colorado, Boulder
- MS, Chemical Engineering, Stanford University
- PhD, Chemical Engineering, Stanford University
Gerald Herman
Executive Vice President and Chief Financial Officer

- Chief Financial Officer since June 2018, after being named Interim Chief Financial Officer in March 2018.
- Joined Bruker in 2016 as Vice President and Corporate Controller.
- Track record of senior executive positions with various publicly traded companies including as Corporate Vice President—Clinical Operations of PAREXEL International from 2014 to February 2016, and as Corporate Vice President & Controller-Finance of PAREXEL from 2008 to 2013.

PRIOR TO BROUKER
- VP—Clinical Operations and Controller of PAREXEL
- VP—Corporate Controller of Presstek
- Financial, consulting and accounting roles at various organizations, including as Senior Manager at Arthur Andersen

EDUCATION
- MBA from the University of Chicago
- MS in Taxation from Bentley University
- Certified Public Accountant (CPA)
Rohan A. Thakur, Ph.D.
President, Life Sciences Mass Spectrometry Division

- President, Bruker LSMS Division, with responsibility for global operations.
- Over 25 years of experience in mass spectrometry, including 14 years in applications and MS development and owner of several patents in the field of mass spectrometry.
- Over 20 years managing businesses with full P&L responsibility of multi-national corporations.
- Strong track record of building a high-growth, high-margin organization that outperforms competition.
- Deep expertise in MS related R&D, marketing and sales which fosters strategy, R&D focus, product development, market expansion as well as mergers and acquisitions
- Exceptional leader in KOL network management

EDUCATION
- MS, Chemistry, Kansas State University
- Ph.D., Chemistry, Kansas State University
- Post-doctoral studies, Rutgers University

PRIOR TO BRUKER
- Global Marketing Director, Mass Spectrometry Solutions, Thermo Fisher Scientific
- Director Drug Discovery, Specialized Mass Spectrometry, Taylor Technology
- Executive Director, Strategic Initiatives, PharmaNet Development Group, Inc.
Xiaomei Li, Ph.D.
Vice President and GM, Bruker Fluorescence Microscopy Business Unit

- Vice President and GM, Bruker FM Business Unit, with responsibility for the business unit’s global Operations
- Over 8 years managing the FM Business Unit
- ~ 30 years of experience in scientific Instrumentation business in various roles
- Successful track record of turning around business becoming #1 in neuroscience research market with fast growth and profitability in strong competition environment. Extensive experience in sales, marketing and product management in scientific instrumentation

PRIOR TO BRUKER
- Senior Director, Veeco Instruments, Inc.
- Product Manager, Thermo Fisher Scientific, Inc.
- Application Scientist, Park Scientific, Inc.
- Postdoctoral Researcher, Univ. of Pennsylvania

EDUCATION
- BS, Physics, Fudan University, China
- MS, Physics, Vanderbilt University
- PhD, Applied Physics, Yale University
Kunal K. Ghosh, Ph.D.
CEO, Inscopix

EXECUTIVE BIO

CEO, Inscopix, leading the Inscopix Business Unit post-acquisition.

Built Inscopix to >$20M in annual revenues, 80 FTEs, and into a recognized global leader in head-mounted fluorescence microscopy for brain imaging in freely-behaving subjects.

Co-inventor of head-mounted fluorescence microscope (Miniscope) technology.

PRIOR TO BRUKER


EDUCATION

- BS, Electrical Engineering, University of Pennsylvania
- BS, Economics, Wharton School, University of Pennsylvania
- MS, Electrical Engineering, Stanford University
- PhD, Electrical Engineering, Stanford University